ETROP

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。本研究的总体目标是实现早产儿视网膜病变（ROP）患者视觉和结构结局的临床重要改善。主要目的是确定无血管视网膜的选择性早期消融是否比无血管视网膜的常规定时消融更有效地降低由于ROP导致的失明的发生率。次要目的是评价风险分析程序（RM-ROP 2）在识别进展为不利结构结局的高风险患眼方面的有效性和安全性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The overall goal of this study is to achieve clinically important improvements in the visual and structural outcome of patients with retinopathy of prematurity [ROP]. The primary aim is to determine whether selective, earlier ablation of the avascular retina is more effective than conventionally timed ablation of the avascular retina in reducing the incidence of blindness due to ROP. The secondary aim is to evaluate the efficacy and safety of the Risk Analysis Program (RM-ROP2) in the identification of eyes at high risk for progression to unfavorable structural outcome.